|
市場調査レポート
商品コード
1532135
バスキュラーアクセスデバイスの世界市場の評価:製品タイプ別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年)Vascular Access Devices Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
||||||
カスタマイズ可能
|
バスキュラーアクセスデバイスの世界市場の評価:製品タイプ別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年) |
出版日: 2024年08月13日
発行: Market Xcel - Markets and Data
ページ情報: 英文 237 Pages
納期: 3~5営業日
|
世界のバスキュラーアクセスデバイスの市場規模は、2023年の36億3,000万米ドルから2031年に57億1,000万米ドルに達すると予測され、予測期間の2024年~2031年にCAGRで5.83%の成長が見込まれます。疾病負担の増加、入院の増加、医療制度の改善により、市場は予測期間にかなりのペースで拡大する見込みです。
バスキュラーアクセスデバイスは、血管内に薬剤、液体、血液、栄養素を投与するために使用される挿入物です。これらのデバイスには、末梢挿入型中心静脈カテーテル(PICC)、中心静脈カテーテル、植込み型ポート、末梢静脈カテーテル(PIVC)などが含まれます。医療サービスや医療機器の絶え間ない進化に伴い、バスキュラーアクセスデバイスも設計、材料、イメージング技術の統合の面で進化してきました。バスキュラーアクセスデバイスの進歩により、生体適合性、柔軟性、新材料の採用が向上し、患者の転帰と生活の質が向上しています。バスキュラーアクセスデバイスに対する需要の向上は、生活習慣病による負担の増加、技術の進歩、低侵襲手術へのニーズなどによって促進されています。メーカー各社は一貫して、患者の予後を改善し合併症を減らすため、機器の設計や材料の改良に取り組んでいます。
例えば、Teleflex Incorporatedは2024年5月、Arrow EZ-IO Intraosseous Access Procedure Trayを発売し、骨内バスキュラーアクセスポートフォリオを強化しました。これには骨内アクセスに必要なすべてのコンポーネントが含まれており、無菌環境で使用可能な初のFDA認可バッテリー駆動ドライバーを搭載しています。このトレイは、迅速かつ正確に挿入できるように設計されており、緊急時にバスキュラーアクセスを得る際に臨床医が直面する課題に対応しています。しかし、感染症や敗血症など、カテーテルの長期使用に伴うリスクが市場成長の課題となる可能性があります。
慢性疾患の負担の増加が市場規模を拡大
がん、心血管疾患、泌尿器疾患などの慢性疾患の有病率の増加により、慢性疾患の負担は世界的に増加傾向にあり、化学療法、透析、投薬などの治療に頻繁かつ長期的なバスキュラーアクセスが必要となるため、中心静脈カテーテルや末梢静脈カテーテルなどのさまざまなタイプのバスキュラーアクセスデバイスに対する需要が高まっています。負担の増加のもう1つの要因は、このような疾患にかかりやすい老年人口の増加です。進行中のシナリオにより、バスキュラーアクセスデバイスの需要は今後さらに増加すると予測されます。
例えばNational Institute of Health(NIH)は、50歳以上の成人が少なくとも1つの慢性疾患に罹患し、その数は2020年の7,152万2,000人から2050年に1億4,266万人へと99.5%増加すると予測しています。世界の全死亡者の47%に相当する推定4,800万人が2060年までに深刻な健康関連の苦しみで死亡すると予測され、2016年の2,600万人から87%増加します。このうち83%は中低所得国で起こると予測されています。世界保健機関(WHO)の推計によると、2050年までに地球上の60歳以上の人口は2倍になり、21億人となります。
市場需要を促進する設計の改良
バスキュラーアクセスデバイスには、中心静脈カテーテル(CVC)、自己血管動静脈瘻(AVF)、人工血管動静脈瘻(AVG)などがあります。CVCの先端と被覆の設計における革新は開存性と血流速度を改善しました。AVFはCVCに比べ、凝固や感染を起こしにくく、信頼性が高く十分な血流量を確保できるため、好まれています。このような設計の改良により、AVF形成デバイスは市場の成長につながる大きな勢いを有しています。市場企業は、設計を強化した革新的な製品を発売する機会を狙っています。例えば2023年9月、Laminate Medical Technologiesは、透析アクセス用のAVF形成デバイス、VasQ External Vascular Supportの米国FDA認可を取得したと発表しました。注目すべきは、VasQを使用した臨床試験において、患者の80%が治療開始後1年以内に中心静脈カテーテルを抜去することができ、従来のAVFと比較して感染のリスクが減少したことです。VasQはAVF形成中に血管を構造的に補強し、よりよい動脈流と機能性を促進します。
当レポートでは、世界のバスキュラーアクセスデバイス市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。
Global vascular access devices market is projected to witness a CAGR of 5.83% during the forecast period 2024-2031, growing from USD 3.63 billion in 2023 to USD 5.71 billion in 2031. With increasing disease burden, rising hospitalization, and an improved healthcare system, the market of vascular access devices is anticipated to expand at a notable pace during the forecast period.
Vascular access devices are insertions used to administer drugs, fluids, blood, and nutrients in blood vessels. These devices include peripherally inserted central catheters (PICCs), central venous catheters, implantable ports, and peripheral intravenous catheters (PIVCs). With the never-ending evolution of healthcare services and medical devices, vascular access devices have evolved in terms of design, material, and integration of imaging technologies in it. Advancements in vascular access devices have improved biocompatibility, flexibility, and the adoption of novel materials, enhancing patient outcomes and quality of life. The rising demand for vascular access devices is driven by the growing burden of lifestyle diseases, technological advancements, and the need for minimally invasive procedures. Manufacturers are consistently working to enhance device design and materials to improve patient outcomes and reduce complications.
For instance, in May 2024, Teleflex Incorporated launched the Arrow EZ-IO Intraosseous Access Procedure Tray, enhancing its intraosseous vascular access portfolio. It includes all necessary components for intraosseous access, featuring the first FDA-cleared battery-powered driver that can be utilized in sterile environments. The tray is designed for quick and precise insertion, addressing the challenges clinicians face in obtaining vascular access during emergencies. However, risks associated with long-term use of catheters, such as infections and sepsis may pose challenges for market growth.
Rising Burden of Chronic Diseases to Increase the Market Size
The chronic disease burden is on a rise globally, owing to the increasing prevalence of chronic diseases, such as cancer, cardiovascular and urological disorders, and others, which necessitates frequent and long-term vascular access for treatments such as chemotherapy, dialysis, and medication administration, thereby driving the demand for various types of vascular access devices, including central venous catheters and peripheral IV catheters. Another factor contributing to the growing burden is the rising geriatric population, highly prone to catching such diseases. With the ongoing scenario, the future demand for vascular access devices is anticipated to increase further.
For instance, the National Institute of Health (NIH), anticipates that the number of adults 50 years and older suffer from at least one chronic disease, which will increase by 99.5% from 71.522 million in 2020 to 142.66 million in 2050. An estimated 48 million people, or 47% of all deaths globally, are expected to die from severe health-related suffering by 2060, an 87% increase from 26 million in 2016. It is anticipated that 83% of these deaths will occur in low and middle-income countries. As per World Health Organization (WHO) estimates, by 2050, there will be twice as many people 60 years or older on the planet with the population of 2.1 billion.
Design Improvements to Drive Market Demand
The established types of vascular access devices include central venous catheters (CVCs), arteriovenous fistulas (AVFs), and arteriovenous grafts (AVGs). Innovations in CVC tip and coating design have improved patency and blood flow rates. AVFs are preferred over CVCs as they are less prone to clotting and infection while providing reliable and adequate blood flow rates. With such design enhancements, the AVF creation devices have significant traction leading to market growth. Market players are taking chances to launch innovative products with enhanced designs. For instance, in September 2023, Laminate Medical Technologies announced that it received US-FDA clearance for its VasQ External Vascular Support device, designed to create AVFs for dialysis access. Notably, 80% of patients in trials using VasQ were able to remove central venous catheters within their first year of treatment, reducing the risk of infection compared to traditional AVFs. The VasQ device provides structural reinforcement to the vessels during AVF creation, promoting better arterial flow and functionality.
Drug Administration Application to Dominate Vascular Access Devices Market Share
The drug administration application of the vascular access devices market is anticipated to cover the highest market share. As these devices provide reliable, long-term access to the bloodstream, which is essential for patients needing frequent or prolonged intravenous therapies, such as chemotherapy or chronic disease management, reducing complications associated with traditional IV lines, such as infections and vein irritation, by minimizing the need for repeated needle sticks. A recent study published in the British Medical Journal in July 2024 examined the effectiveness of vascular access devices (VADs) in reducing infection rates among hospitalized patients. The study concluded that VADs along with specific safety measures reduce the chances of infection.
North America Dominates the Global Vascular Access Devices Market Share
North America is anticipated to hold major market share of the global vascular access devices market. North America's leadership in the demand for vascular access devices is attributed to its advanced healthcare infrastructure, rising prevalence of chronic diseases, technological innovations, supportive regulations, and demographic trends favoring increased healthcare needs. According to the United States Renal Data System 2023 Annual Data Report, published in April 2024, more than 85% of individuals who began hemodialysis used a catheter. Additionally, nearly three-quarters of the United States population started without permanent access, a significant increase from about 65% in 2018. This rise in number clearly shows an increasing consumption of such devices in North America causing it to hold the largest market share among other regions.
Future Market Scenario (2024 - 2031F)
The vascular access devices market has witnessed several remarkable futuristic advancements that are anticipated to shape the future of such devices. These advancements include wearable technology, remote monitoring of atrioventricular flow, use of biocompatible materials for product design, 3D printing technology, image-guided vascular access devices, and others. The USFDA approval of WavelinQ and Ellipsys, two vascular access devices that facilitate the creation of arteriovenous fistulas (AVFs) using minimally invasive techniques has paved a new path for more products in line with endovascular fistula creation. The of the most revolutionary advancement is the image-guided vascular access system, Ultreon 1.0 launched by Abbott in October 2023. This platform uses near-infrared light to provide high-definition, precise imaging from within the blood vessels, allowing the healthcare professional precise access to blood vessels even in the most complex anatomies.
Key Players Landscape and Outlook
The market witnessed some substantial market deals such as acquisitions, regulatory approvals, and product launches to expand the share of key players in the global vascular access devices market. In June 2023, Merit Medical announced two strategic acquisitions totaling USD 132.5 million to enhance its dialysis catheter portfolio. Merit Medical is acquiring dialysis catheters and a sealant system from AngioDynamics for USD 100 million, which complements its biopsy devices by preventing pneumothorax during lung biopsies. Additionally, Merit is purchasing the Surfacer catheter system from Bluegrass Vascular Technologies for USD 32.5 million, which facilitates central venous access.
In November 2023, BD launched the SiteRite 9 Ultrasound System, which is an advanced vascular access ultrasound designed to enhance clinician efficiency in placing peripherally inserted central catheters (PICCs), central venous catheters, and IV lines. SiteRite 9 aims to increase first-attempt insertion success and reduce unnecessary needlesticks, supporting BD's vision of a One-Stick Hospital Stay. The system received 510(k) Clearances in September 2023 and is available in the United States
market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.